This article was downloaded by: On: 26 January 2011 Access details: Access Details: Free Access Publisher Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37- 41 Mortimer Street, London W1T 3JH, UK



### Organic Preparations and Procedures International

Publication details, including instructions for authors and subscription information: <http://www.informaworld.com/smpp/title~content=t902189982>

## MICROWAVE-ASSISTED SYNTHESIS OF ERYTHROMYCIN DERIVATIVES ON SODIUM ACETATE-DOPED CALCIUM CHLORIDE

Kai Baoª; Wei-Ge Zhangª; Ying-Wei Quª; Chuan-Liang Zhangª; Liang Tianª; Mao-Sheng Chengª a Department of Medicinal Chemistry, Shenyang Pharmaceutical University, Shenyang, PR China

To cite this Article Bao, Kai , Zhang, Wei-Ge , Qu, Ying-Wei , Zhang, Chuan-Liang , Tian, Liang and Cheng, Mao-Sheng(2008) 'MICROWAVE-ASSISTED SYNTHESIS OF ERYTHROMYCIN DERIVATIVES ON SODIUM ACETATE-DOPED CALCIUM CHLORIDE', Organic Preparations and Procedures International, 40: 1, 97 — 101

To link to this Article: DOI: 10.1080/00304940809356643 URL: <http://dx.doi.org/10.1080/00304940809356643>

# PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use:<http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

#### **MICROWAVE-ASSISTED SYNTHESIS OF ERYTHROMYCIN DERIVATIVES ON SODIUM ACETATE-DOPED CALCIUM CHLORIDE**

*Submitted by*  (05/04/07) Kai Bao, Wei-Ge Zhang,\* Ying-Wei Qu, Chuan-Liang Zhang, Liang Tian and Mao-Sheng Cheng\*

> *Department of Medicinal Chemistry* **Shenyang Pharmaceutical University** *Shenyang 110016, P. R. CHINA e-mail: zhangweige2000@sina.com or maoshengcheng @263. com*

Erythromycin **(la)** has been clinically used for more **than** 50 years.' In addition to its antimicrobial effect, the unique anti-inflammatory activity of erythromycin derivatives has been reported as a new therapeutic potential.<sup>2</sup> In our effort to maximize the anti-inflammatory activity of erythromycin, the derivative of erythromycin **(3a),** which exhibited potent *in vitro* anti-inflammatory activity, $3$  was selected as one of our target compounds.

The conventional synthesis of **3a** involves the intramolecular transesterification of 8,9 anhydroerythromycin 6,9-hemiketal **(2a),** obtained by dehydration of **la** dissolved in glacial acetic acid, with potassium carbonate in refluxing methanol for 90 min.<sup>4</sup> The overall yield of the two steps is **37%.** On the other hand, compound **3a** could be prepared directly by heating **la** at 70°C for 24 hr with a **3:1** mixture of pyridine and acetic acid to afford a mixture of **2a** and **3a** in 19% and 71% yields respectively.<sup>5</sup> Herein, we report a facile and straightforward synthesis of **3a** from **la** under microwave irradiation in the absence of solvents.



 $3bR = H$ 

To find the optimal conditions, the reaction was carried out on various types of solid supports respectively **as** presented in *Table 1.* When CaCI, was used as solid support in this reaction, we found that the reaction was more efficient and **3a** could be prepared in 19% yield. In addition, the yield of **3a** increased to 24% when CaCl, was doped with NaOAc (the molar ratio of CaCI, to NaOAc was *5:* 1 ). To the best of our knowledge, the use of CaC1, **as** adsorbent under microwave irradiation has never been documented. We observed that the ratio of CaCl,, NaOAc and water of the solid support affects the yields of **2a** and **3a.** Therefore, we examined the influence of various ratios on the yields of this reaction and found that the optimal molar ratio of CaCI,, NaOAc and water is 2: 1 :2.4 *(Table* 2).





a) The MW power was set at 400W and the temprature was controlled automatically at 190°C by intermittent irradiation.

CaCl <sub>2</sub> :NaOAc:H <sub>2</sub> O	Time (min)	Yield $(\%)$	
		2a	3a
20:1:0	30		
10:1:0	30	27	
5:1:0	30	30	24
2:1:0	30	35	31
2:1:3.5	30	34	23
2:1:2.4	20	44	35
2:1:2.4	30	24	52
2:1:2.4	40	22	53

**Table 2.** Influence of Ratio of CaCI,, NaOAc, H,O on the Yields of **2a** and **3a8** 

a) Thc MW power was set at 400W and the temprature was controlled automatically at 190°C **by**  intermittent irradiation.

It was shown that the yield of compound **3a** increased steadily to 52% when the rcaction time was increased to 30 min while the yield of **2a** decreased if the time of irradiation was longcr than 20 min. Increasing the time **to** over 30 min did not affect the composition of compounds **la, 2a** and **3a.** 

In order to verify the effect of this reaction, N-demethylated erythromycin A **(lb)**  obtained by the treatment of 1a with iodine and NaOAc,<sup>6</sup> was coated onto the surface of NaOAc- $CaCl<sub>2</sub>$ . Under the standardized reaction condition, the N-demethylated derivative of erythromycin A  $(3b)$  which has been shown to possess some anti-inflammatory activity <sup>7</sup> and N-demethylated 8,9- anhydroerythromycin A 6,9-hemiketal **(2b)** were obtained in 48% and 20% yields, respectively.

In conclusion, we found an economical and efficient method to finish the synthesis of ring-contracted derivatives of erythromycin on NaOAc-doped CaCI, *via* intramolecular dehydration and transesterification under microwave irradiation. It is to be noted that the use of water soluble CaCI, affords a facile isolation of the desired products.

#### **EXPERIMENTAL SECTION**

The reactions were carried out in a laboratorial microwave oven (XH-100) made in Beijing Xianghu Science & Technology Development Co., LTD. The reactions were conducted at a MW power setting of 400W and the temperature of the reaction mixture ( 190°C) was measured by an immersed platinum resistance thermometer. The temperature of the mixture was controlled at 190°C automatically by discontinuous microwave irradiation during the reactions. Melting points for the compounds were determined using a hot-stage microscope and are uncorrected. **'H** and  $^{13}$ C-NMR spectra were obtained in CDCI, solution on Bruker ARX-300 spectrometers with TMS as the internal reference. MS spectra were acquired using JMS-DX300 spectrometer. Column chromatography was performed on silica gel (200-300 mesh) from Qingdao Ocean Chemicals. Unless otherwise noted, all the materials were obtained from commercially available sources and were used without purification.

**Ring-contracted Derivative of Erythromycin (3a). Typical Procedure.-** Anhydrous CaCI, (2.0g, 18.20mmol) and anhydrous NaOAc (0.75g, 9.15mmol) were dissolved in water (5 mL) and dried in a drying oven at 90°C for about 48 hr (till the weight of the mixture was about 3.14g and the molar ratio of CaCI, to NaOAc to H,O was found to be 2:1:2.4). To a solution of erythromycin A (0.2 **g,** 0.27mmol) in EtOAc (10 mL), 2g of the solid support was added. EtOAc was removed under reduced pressure until the mixture was powdery. Then the mixture was irradiated three times under microwave at 400W, 190°C for 10 min. After cooling, H,O (20 mL) was added and the solution was extracted with chloroform (3 x 10 mL), washed with saturated brine, and dried over anhydrous  $Na, SO<sub>4</sub>$ , filtered and the organic phase was evaporated to dryness. The resulting crude product was purified by column chromatography on silica gel eluting with chloroform-methanol-ammonium hydroxide solution (10:0.5:0.01 to 10: 1 *:0.05)* to give compound **2a**  (0.047g, 24%) and compound **3a** (O.lOg, 52%) as a white amorphous solid respectively.

**3a:** mp. 127-130°C, *lit.3* mp. 126-130°C; IR(KBr): 3509.8, 2973.7, 2937.1, 2877.3, 1702.8, 1457.9, 1380.8, 1319.1, 1256.1, 1166.7, 1114.7, 1076.1, 1049.1, 1016.3 cm-'; 'H-NMR (CDCI,):  $\delta$  2.83(dd, 1H, J = 10.0, 7.0), 4.27(dd, 1H, J = 10.0, 3.0), 1.76(ddq, 1H, J = 3.0, 9.5, 7.0), 3.70(d, IH, *J* = 9.5),2.78(AMX, IH, *J* = 16.0, 1 *S),* 2.03(AMX, IH, *J* = 16.0, **lS),** 2.93(dq, lH, *J* = 2.7, 7.0), 5.06(d, IH, *J=* 2.7), 2.83(dd, lH, *J=* 10.0,2.5), 1.68(m, IH), 1.36(m, IH), 0.98(d, 3H, *J=*  7.0), I .27(s, 3H), 1.10(d, 3H, *J* = 7.0), 1.42(s, 3H), 1.55(br **s,** 3H), 1.22(d, 3H, J = 7.1), 1.20(s, 3H), 4,33(d, IH, J = 7.0), 3.20(dd, IH, J = 7.0, lO.O), 2.48(m, IH), 1.68(m, IH), 1.26(m, lH),  $3.48(m, 1H)$ ,  $1.19(d, 3H, J = 7.0)$ ,  $2.29(s, 6H)$ ,  $4.89(d, 1H, J = 7.0)$ ,  $2.38(d, 1H, J = 10.0, 7.0)$ , 1.51(dd, IH, J = 10.0, 7.0), 3.03(d, lH, J = 9.5),4.07(m, IH), 1.33(m, 3H), 1.21(s, **3H),** 3.28(s, 3H); <sup>13</sup>C-NMR (CDCl,):  $\delta$  175.72, 46.56, 80.20, 38.49, 81.22, 85.77, 43.15, 101.04, 149.34, 31.41, 77.49, 76.28, 77.23, 22.27, 11.68, 14.94, 9.13, 26.49, 10.80, 11.05, 16.39, 103.61, 70.69, 65.03, 28.57, 68.64, 21.01, 40.06, 97.27, 34.95, 72.44, 77.83, **65.07,** 21.21,49.11, 18.12;HRMS (FAB) *m*/z: Calcd for C<sub>37</sub>H<sub>66</sub>NO<sub>12</sub> [M+H]<sup>+</sup>716.4585. Found 716.4581.

The N-demethylated ring-contracted derivative of erythromycin **(3b)** was obtained in the similar way as **3a.** 

3b: mp. 190-193"C, *lk8* **mp.** 193-195°C; IR(KBr): 331 1.2, 2969.8, 2931.3, 2861.8, 1706.7, 1459.8, 1378.9, 1263.1, 1166.7, 1128.2, 1097.3, 1074.2, 1037.5, 1018.2 cm-'; 'H-NMR (CDCI,):  $\delta$  2.80(dd, 1H, J = 10.0, 7.0), 4.23(dd, 1H, J = 10.0, 2.8), 1.78(ddq, 1H, J = 2.8, 9.5, 7.0), 3.78(d, lH, J = 9.9, 2.74(AMX, lH, J = 14.6, 1.3, 2.05(AMX, lH, J = 14.6, **lS),** 3.05(m, IH), 5.10(d, 1H, J = 2.6), 2.87(dd, 1H, J = 10.0, 2.5), 1.71(m, 1H), 1.36(m, 1H), 1.00(d, 3H, J = 7.0), 1.28(s, 3H), l.ll(d, 3H, J = 7.0), 1.43(s, 3H), 1.62(br **s,** 3H), 1.22(d, 3H, J = 7.0), 1.24(s, 3H), 4.37(d, IH, J = 7.0), 3.25(dd, IH, J = 7.0, lO.O), 2.51(m, lH), 1.82(m, IH), 1.28(m, lH), 3.59(m, 1H), 1.20(d, 3H, J = 7.0), 2.38(s, 3H), 4.95(d, lH, J = 7.2), 2.37(dd, lH, J = 10.0,7.2), 1.41(dd, lH, J  $= 10.0, 7.2$ ), 3.06 (d, 1H, J = 9.5), 4.12(m, 1H), 1.34(m, 3H), 1.24(s, 3H), 3.28(s, 3H); <sup>13</sup>C-NMR (CDC1,): 6 175.8,46.76, 80.25, 38.51, 81.67, 86.00, 43.22, 101.29, 149.56, 31.56, 77.47, 76.53, 77.20, 22.50, 11.88, 15.08, 9.89, 26.58, 11.06, 11.23, 16.53, 103.27, 74.41, 60.00, 36.84, 68.59, 20.95, 32.92, 97.38, 35.11, 72.44, 77.97, 65.27, 18.27, 21.42, 49.29;HRMS **(FAB)** *dz:* Calcd for  $C_{36}H_{63}NO_{12}Na$  [M+Na]+724.4248. Found 724.4230.

#### **REFERENCES**

- 1. J. M. McGuire, R. L. Bunch, R. C. Anderson, H. E . Boaz, E. H. Flyn, H. M. Powell and J. **W.** Smith, *Antibiot. Chemother.,* 2,281 (1952).
- 2. **A.** Mereu, E. Moriggi, M. Napoletano, C. Regazzoni, **S.** Manfredini, T. P. Mercurio and F. Pellacini, *Bioorg. Med. Chem. Len.,* 16,5801 (2006).
- 3. **S.** Omura, K. Akagawa and T. Sunazuka. *US Patent* 2003186900; *Chem. Abstr.,* 139:286308 (2003).
- 4. H. A. Kirst, J. A. Wind and J. W. Paschal, *J. Org. Chem.,* 52,4359 (1987).
- 5. I. 0. Kibwage, R. Busson, **C.** Janssen, J. Hoogmartens and H. Vanderhaeghe, *J. Org. Chem.,*  52,990 ( 1987).
- 6. R. Faghih, H. N. Ncllans, P. **A.** Lartey, **A.** Petersen, K. Marsh, Y. L. Bennani and J. J. Plattner, *Bioorg. Med. Chem. Lett.*, 8, 805 (1998).
- 7. H. Gouda, T. Sunazuka, K. Yoshida, **A.** Sugawara, **Y.** Sakoh, **S.** Omura and **S.** Hirono, *Bioorg. Med. Chem. Lett.,* 16,2496 (2006).
- *8.* I. 0. Kibwage, G. Janssen, R. Busson J. Hoogmartens and H. Vanderhaeghe, *J. Antibiot.,* **40,**  1 (1987).

\*\*\*\*\*\*\*

### **IODINE AS** *AN* **EFFICIENT CATALYST FOR THE SYNTHESIS OF BENZIMIDAZOLES** *AND* **IMIDAZOLINES FROM PRIMARY ALCOHOLS AND DIAMINES**

Yi-Ming Ren and Chun Cai\*

*Submitted by*  (03/ 1 *5/07)* 

> *Chemical Engineering College Nanjing University of Science and Technology Nanjing 210094, P. K.* CHINA *E-mail: c.cai@mail,njust. edu. cn*

Benzimidazoles and imidazolines are very useful intermediates for the development of molecules of pharmaceutical or biological interest. Substituted benzimidazole derivatives have found applications in diverse therapeutic areas including antiulcers, antihypertensives, antivirals, antifungals, anticancers, and antihistaminics to name just a few.<sup>1</sup> In addition, imidazoline units are also used as synthetic intermediates, chiral auxiliaries, chiral catalysts and ligands for asymmetric catalysis.<sup>2</sup> Due to their wide range of pharmacological activity, industrial and synthetic applications, a number of methods have been reported for the synthesis of benzimidazoles and imidazolines, which include preparation from esters using aluminium organic reagents as the catalyst,<sup>3a</sup> the reaction between *N*-ethoxycarbonylthioamides with 1,2-diamines,<sup>3b</sup> and the reaction of aldehydes with 1,2-diamines followed by N-halosuccinimides  $(X = Cl, Br, I)<sup>3c</sup>$  Recently, several methods have been developed, where azalactones, $4^a$  2-aryl-1,1-dibromoethanes, $4^b$ nitriles<sup>4c</sup> and amino amides<sup>4d</sup> have been used as starting materials for this synthesis. However, many of the synthetic protocols suffer from disadvantages, such as requring anhydrous<sup>4a</sup> or harsh reaction conditions,<sup>3a</sup> prolonged reaction times,<sup>3c</sup> use of metals and expensive reagents,<sup>3a</sup> etc.

Recently, molecular iodine<sup>5</sup> has received considerable attention as an inexpensive, nontoxic, readily available catalyst for various organic transformations to afford the corresponding